| Year |
Citation |
Score |
| 2018 |
Davison C, Chevallier OP, Knowlson C, McKechnie M, Carson R, Esteve J, Wilson R, Ladner RD, LaBonte MJ. Abstract 3836: Imbalanced nucleotide metabolism sensitizes breast cancer cells to anthracyclines Cancer Research. 78: 3836-3836. DOI: 10.1158/1538-7445.Am2018-3836 |
0.453 |
|
| 2015 |
Lawler M, Gavin A, Salto-Tellez M, Kennedy RD, Van Schaeybroeck S, Wilson RH, Harkin DP, Grayson M, Boyd RE, Hamilton PW, McArt DG, James J, Robson T, Ladner RD, Prise KM, et al. Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program. Cancer. PMID 26695702 DOI: 10.1002/Cncr.29814 |
0.369 |
|
| 2015 |
Benhaim L, Zhang W, Wakatsuki T, Yang D, Gerger A, Bohanes P, Paez D, Loupakis F, LaBonte MJ, Ning Y, El-Khoueiry R, Ladner R, Wilson P, Zhang H, Giamas G, et al. Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer. The Pharmacogenomics Journal. 15: 235-40. PMID 25287073 DOI: 10.1038/Tpj.2014.58 |
0.362 |
|
| 2014 |
Wilson PM, Danenberg PV, Johnston PG, Lenz HJ, Ladner RD. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nature Reviews. Clinical Oncology. 11: 282-98. PMID 24732946 DOI: 10.1038/Nrclinonc.2014.51 |
0.356 |
|
| 2013 |
Wilson PM, Labonte MJ, Martin SC, Kuwahara ST, El-Khoueiry A, Lenz HJ, Ladner RD. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer Investigational New Drugs. 31: 845-857. PMID 23299388 DOI: 10.1007/S10637-012-9914-7 |
0.309 |
|
| 2013 |
Wilson PMD, Wakatsuki T, Loupakis F, Zhang W, Yang D, Stintzing S, Ning Y, Volz NB, El-Khoueiry RE, Li JE, Labonte MJ, Sunakawa Y, Maus MKH, Ladner RD, Barzi A, et al. Association of a polymorphism in amphiregulin with worse prognosis in metastatic colorectal cancer patients treated with cetuximab. Journal of Clinical Oncology. 31: e14543-e14543. DOI: 10.1200/Jco.2013.31.15_Suppl.E14543 |
0.362 |
|
| 2013 |
Ladner RD, Kahn M, Yang D, Stintzing S, Zhang W, Wakatsuki T, Ning Y, Volz NB, Li JE, Labonte MJ, Wilson PMD, Kardosh A, Lenz H. Risk of tumor-related death in stage I-III colon cance based on gender and tumor location. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E14538 |
0.338 |
|
| 2012 |
Lee YS, Choi I, Ning Y, Kim NY, Khatchadourian V, Yang D, Chung HK, Choi D, LaBonte MJ, Ladner RD, Nagulapalli Venkata KC, Rosenberg DO, Petasis NA, Lenz HJ, Hong YK. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. British Journal of Cancer. 106: 1833-41. PMID 22617157 DOI: 10.1038/Bjc.2012.177 |
0.41 |
|
| 2012 |
Ning Y, Labonte MJ, Zhang W, Bohanes PO, Gerger A, Yang D, Benhaim L, Paez D, Rosenberg DO, Nagulapalli Venkata KC, Louie SG, Petasis NA, Ladner RD, Lenz HJ. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Molecular Cancer Therapeutics. 11: 1353-64. PMID 22391039 DOI: 10.1158/1535-7163.Mct-11-0915 |
0.451 |
|
| 2012 |
Wilson PM, LaBonte MJ, Lenz HJ, Mack PC, Ladner RD. Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer Molecular Cancer Therapeutics. 11: 616-628. PMID 22172489 DOI: 10.1158/1535-7163.Mct-11-0781 |
0.41 |
|
| 2012 |
LaBonte MJ, Wilson PM, Yang D, Zhang W, Ladner RD, Ning Y, Gerger A, Bohanes PO, Benhaim L, El-khoueiry R, El-khoueiry A, Lenz HJ. The cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer Annals of Oncology. 23: 1455-1464. PMID 21989330 DOI: 10.1093/Annonc/Mdr445 |
0.371 |
|
| 2012 |
Labonte MJ, Bohanes PO, Yang D, Loupakis F, Wilson PMD, Gerger A, Ning Y, Wakatsuki T, Zhang W, Benhaim L, Ladner RD, El-Khoueiry AB, El-Khoueiry R, Iqbal S, Lenz H. Novel colon cancer tumor suppressor gene, β-defensin 1, to predict recurrence in patients with stage II and III colon cancer. Journal of Clinical Oncology. 30: 3622-3622. DOI: 10.1200/Jco.2012.30.15_Suppl.3622 |
0.433 |
|
| 2012 |
Ladner RD, Gerger A, Zhang W, Labonte MJ, Yang D, Lenz F, Lenz C, Bohanes PO, Ning Y, Winder T, Wilson PMD, Benhaim L, El-Khoueiry R, El-Khoueiry AB, Iqbal S, et al. Association of genetic variants in obesity-related genes with tumor recurrence in stage II/III colon cancer. Journal of Clinical Oncology. 30: 3584-3584. DOI: 10.1200/Jco.2012.30.15_Suppl.3584 |
0.398 |
|
| 2011 |
Ladner RD, Zhang W, Labonte MJ, Yang D, Ning Y, Gerger A, Bohanes PO, Winder T, El-Khoueiry AB, Iqbal S, Petasis N, Lenz H. Prediction of tumor recurrence in stage II colon cancer through genetic variants in formyl peptide receptor 2 (FPR2). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3604. PMID 28020863 DOI: 10.1200/Jco.2011.29.15_Suppl.3604 |
0.38 |
|
| 2011 |
Ou CY, LaBonte MJ, Manegold PC, So AYL, Ianculescu I, Gerke DS, Yamamoto KR, Ladner RD, Kahn M, Kim JH, Stallcup MR. A coactivator role of CARM1 in the dysregulation of β-catenin activity in colorectal cancer cell growth and gene expression Molecular Cancer Research. 9: 660-670. PMID 21478268 DOI: 10.1158/1541-7786.Mcr-10-0223 |
0.372 |
|
| 2011 |
LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, Lenz HJ, Ladner RD. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Research. 71: 3635-48. PMID 21464044 DOI: 10.1158/0008-5472.Can-10-2430 |
0.416 |
|
| 2011 |
Gordon MA, Zhang W, Yang D, Iqbal S, El-Khouiery A, Nagashima F, Lurje G, Labonte M, Wilson P, Sherrod A, Ladner RD, Lenz HJ. Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. Pharmacogenomics. 12: 27-39. PMID 21174620 DOI: 10.2217/Pgs.10.163 |
0.41 |
|
| 2011 |
Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, Winder T, Yang D, LaBonte MJ, Wilson PM, Ladner RD, Lenz HJ. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. International Journal of Cancer. Journal International Du Cancer. 128: 2038-49. PMID 20648559 DOI: 10.1002/Ijc.25562 |
0.315 |
|
| 2011 |
Wilson PM, Ladner RD, Lenz HJ. Predictive and prognostic markers in colorectal cancer. Gastrointestinal Cancer Research : Gcr. 1: 237-46. PMID 19262902 |
0.302 |
|
| 2010 |
Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemotherapy and Pharmacology. 65: 979-88. PMID 20062993 DOI: 10.1007/S00280-009-1236-X |
0.391 |
|
| 2010 |
Ladner RD, Ulrich CM, Rankin CJ, Danenberg KD, Danenberg PV, Smalley SR, Makar KW, Benedetti JK, Blanke CD, Lenz H. Association of intratumoral gene expression levels of thymidine phosphorylase (TP) and VEGF with clinical outcome in stage II/III rectal cancer patients treated with 5-fluorouracil and pelvic radiation in a phase III intergroup trial (SWOG 9304). Journal of Clinical Oncology. 28: 3640-3640. DOI: 10.1200/Jco.2010.28.15_Suppl.3640 |
0.371 |
|
| 2010 |
Labonte MJ, Yang D, Zhang W, Wilson PM, Ladner RD, Winder T, Bohanes PO, Ning Y, Lenz H. Correlation of cyclin D1, A870G, polymorphism, and clinical outcome in patients with HER2-positive, metastatic breast cancer treated with lapatinib plus capecitabine. Journal of Clinical Oncology. 28: 1015-1015. DOI: 10.1200/Jco.2010.28.15_Suppl.1015 |
0.413 |
|
| 2010 |
LaBonte MJ, Wilson PM, El-Khoueiry A, Lenz H, Ladner RD. Abstract 5438: A novel therapeutic combination with synergistic antitumor activity in colon cancer: The dual tyrosine kinase inhibitor lapatinib and the histone deacetylase inhibitor LBH589 Cancer Research. 70: 5438-5438. DOI: 10.1158/1538-7445.Am10-5438 |
0.467 |
|
| 2010 |
Wilson PM, LaBonte MJ, Ladner RD. Abstract 1623: The nucleotide metabolizing enzyme dUTPase confers resistance to thymidylate synthase inhibition in non-small cell lung cancer cells Cancer Research. 70: 1623-1623. DOI: 10.1158/1538-7445.Am10-1623 |
0.341 |
|
| 2010 |
Wilson PM, LaBonte MJ, El-Khoueiry A, Lenz H, Ladner RD. Abstract A4: Identification of novel histone deacetylase inhibitor-regulated drug targets and a phase I/II trial of vorinostat in combination with 5-fluorouracil in metastatic colorectal cancer Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcme10-A4 |
0.425 |
|
| 2009 |
LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. Bmc Medical Genomics. 2: 67. PMID 19948057 DOI: 10.1186/1755-8794-2-67 |
0.449 |
|
| 2009 |
LaBonte MJ, Manegold PC, Wilson PM, Fazzone W, Louie SG, Lenz HJ, Ladner RD. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. International Journal of Cancer. Journal International Du Cancer. 125: 2957-69. PMID 19536776 DOI: 10.1002/Ijc.24658 |
0.427 |
|
| 2009 |
Fazzone W, Wilson PM, LaBonte MJ, Lenz HJ, Ladner RD. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells International Journal of Cancer. 125: 463-473. PMID 19384949 DOI: 10.1002/Ijc.24403 |
0.452 |
|
| 2009 |
Kumar SR, Scehnet JS, Ley EJ, Singh J, Krasnoperov V, Liu R, Manchanda PK, Ladner RD, Hawes D, Weaver FA, Beart RW, Singh G, Nguyen C, Kahn M, Gill PS. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Research. 69: 3736-45. PMID 19366806 DOI: 10.1158/0008-5472.Can-08-3232 |
0.411 |
|
| 2009 |
Wilson PM, Fazzone W, Labonte MJ, Lenz HJ, Ladner RD. Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage Nucleic Acids Research. 37: 78-95. PMID 19015155 DOI: 10.1093/Nar/Gkn910 |
0.357 |
|
| 2008 |
Labonte MJ, Wilson PM, Fazzone W, Lenz HJ, Ladner RD. Evaluation of the dual tyrosine kinase inhibitor lapatinib in combination with 5-fluorouracil and SN-38 in colon and gastric cell line models. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 14643. PMID 27950214 DOI: 10.1200/Jco.2008.26.15_Suppl.14643 |
0.374 |
|
| 2008 |
Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7884-95. PMID 19047118 DOI: 10.1158/1078-0432.Ccr-07-5165 |
0.415 |
|
| 2008 |
Wilson PM, Fazzone W, LaBonte MJ, Deng J, Neamati N, Ladner RD. Novel opportunities for thymidylate metabolism as a therapeutic target. Molecular Cancer Therapeutics. 7: 3029-37. PMID 18790783 DOI: 10.1158/1535-7163.Mct-08-0280 |
0.407 |
|
| 2008 |
Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM, Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenetics and Genomics. 18: 161-8. PMID 18192902 DOI: 10.1097/Fpc.0B013E3282F4Aea6 |
0.359 |
|
| 2007 |
Rhodes KE, Zhang W, Yang D, Press OA, Gordon M, Vallböhmer D, Schultheis AM, Lurje G, Ladner RD, Fazzone W, Iqbal S, Lenz HJ. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan. Drug Metabolism Letters. 1: 23-30. PMID 19356014 DOI: 10.2174/187231207779814328 |
0.417 |
|
| 2007 |
Wilson PM, Ladner RD, Lenz H. Exploring Alternative Individualized Treatment Strategies in Colorectal Cancer Clinical Colorectal Cancer. 7. PMID 18361804 DOI: 10.3816/Ccc.2008.S.005 |
0.428 |
|
| 2007 |
Ladner RD, Gordon MA, Zhang W, Yang D, Nagashima F, Chang H, Lurje G, Borucka E, Lenz H. Polymorphisms in estrogen receptor beta, interleukin-8, and interleukin-8 receptor associated with clinical outcome in metastatic colorectal cancer (mCRC) patients treated with 5-fluorouracil/oxaliplatin Journal of Clinical Oncology. 25: 4130-4130. DOI: 10.1200/Jco.2007.25.18_Suppl.4130 |
0.401 |
|
| 2007 |
Nagashima F, Zhang W, Gordon M, Chang HM, Lurje G, Borucka E, Yang D, Ladner R, Rowinsky E, Lenz HJ. EGFR, Cox-2, and EGF polymorphisms associated with progression-free survival of EGFR-expressing metastatic colorectal cancer patients treated with single-agent cetuximab (IMCL-0144) Journal of Clinical Oncology. 25: 4129-4129. DOI: 10.1200/Jco.2007.25.18_Suppl.4129 |
0.447 |
|
| 2006 |
Yang D, Schneider S, Azuma M, Iqbal S, El-Khoueiry A, Groshen S, Agafitei D, Danenberg KD, Danenberg PV, Ladner RD, Lenz HJ. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clinical Colorectal Cancer. 6: 305-11. PMID 17241515 DOI: 10.3816/Ccc.2006.N.049 |
0.354 |
|
| 2006 |
Park DJ, Zhang W, Gordon M, Yang DY, Ladner R, Iqbal S, Groshen S, Vallbohmer D, Lenz H, Fazzone W. Lack of association with epidermal growth factor receptor gene polymorphisms with clinical outcome in patients with advanced colorectal cancer treated with platinum-based chemotherapy Journal of Clinical Oncology. 24: 3079-3079. DOI: 10.1200/Jco.2006.24.18_Suppl.3079 |
0.385 |
|
| 2004 |
Koehler SE, Ladner RD. Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition. Molecular Pharmacology. 66: 620-6. PMID 15322254 DOI: 10.1124/mol.66.3. |
0.305 |
|
| 2004 |
Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz HJ, Ladner RD. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels Pharmacogenetics. 14: 319-327. PMID 15115918 DOI: 10.1097/00008571-200405000-00007 |
0.301 |
|
| 2001 |
Ladner RD. The role of dUTPase and uracil-DNA repair in cancer chemotherapy. Current Protein & Peptide Science. 2: 361-370. PMID 12374095 DOI: 10.2174/1389203013380991 |
0.384 |
|
| 2000 |
Webley SD, Hardcastle A, Ladner RD, Jackman AL, Aherne GW. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331. British Journal of Cancer. 83: 792-799. PMID 10952785 DOI: 10.1054/Bjoc.2000.1358 |
0.361 |
|
| 1999 |
Wadler S, Damle S, Haynes H, Kaleya R, Schechner R, Berkenblit R, Ladner RD, Murgo A. Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 1771-8. PMID 10561214 DOI: 10.1200/Jco.1999.17.6.1771 |
0.314 |
|
| 1997 |
Horowitz RW, Zhang H, Schwartz EL, Ladner RD, Wadler S. Measurement of deoxyuridine triphosphate and thymidine triphosphate in the extracts of thymidylate synthase-inhibited cells using a modified DNA polymerase assay. Biochemical Pharmacology. 54: 635-8. PMID 9337081 DOI: 10.1016/S0006-2952(97)00259-1 |
0.327 |
|
| Show low-probability matches. |